Maricann Group Inc. Announces Private Placement of up to $35 Million of Convertible Debenture Units

Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) announced today that it has entered into an agreement with Canaccord Genuity Corp., as lead agent on behalf of a syndicate of investment dealers, including Industrial Alliance Securities Inc., Mackie Research Capital Corporation and Sprott Capital Partners (collectively, the “Agents”) pursuant to which the Company will issue on a private placement basis up to $35,000,000 aggregate principal amount of convertible debenture units (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit.

Read More
Jessica Wong
Maricann Group Inc. Announces Acquisition of NanoLeaf Technologies Inc., Appoints New President and Chief Operating Officer

TORONTO, ONTARIO--(Marketwired - Aug. 22, 2017) - Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI) ("Maricann" or the "Company") announced today that it has entered into an agreement ("Acquisition Agreement") to acquire 100% of the issued and outstanding shares of NanoLeaf Technologies Inc. ("NanoLeaf"), a biotech company possessing licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug delivery formulations. The transaction is expected to be completed by the end of September 2017.

Read More
Jessica Wong
Building An International Cannabis Play

We are initiating coverage of MariCann with a BUY rating, and introducing a price target  of  C$6.00,  based  on  7.0x  FY2021  estimated  EBITDA,  implying  a  111% return  from  the  last  deal  price  of  $2.85,  which  was  completed  in  March  2017. The 7.0x multiple is in the middle of our peer group range of 4.0x - 10.0x, due to MariCann's international partnerships and developing local operations.

Read More
Jessica Wong
In a crowding market, seek differentiation

Health Canada stokes already heated competition. Recent results suggest that many LPs have struggled to ramp production and have therefore missed consensus expectations for sales volumes. While such growing pains are to be expected, on the positive side, quarterly earnings also suggest that cannabis prices have climbed higher due to supply constraints. Read more from Canaccord Genuity on how Maricann is positioned to be a meaningful low-cost producer in Canada.

Read More
Jessica Wong
Maricann Group Inc. Enters Into Letter of Intent

TORONTO, Ontario, Aug. 16, 2017 – Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) and a national provider that services pharmacies across Canada (the “Counterparty”), have agreed to a primary collaborative partnership through a joint initiative to create a pharmacy services program that enables pharmacists to counsel and appropriately educate patients in relation to medicinal cannabis.

Read More
Jessica Wong
Forget the US. Here’s where medical marijuana is really taking off

There's a groundswell of support for cannabis legalisation in the United States, with 29 states, as well as Washington D.C. approved for medicinal cannabis, and eight for lifestyle use.

Things are farther ahead in Canada. Regulations for production and sales have been in place for over three years, and the federal government has introduced a timeline to full federal legalisation for lifestyle use in July 2018. Capacity in Canada for lifestyle alone is projected to reach "5 billion dollars per year to start," according to a recent report from Deloitte.

Read More
Jessica Wong
Maricann Looks To Replicate Canada Success In Newly Legal German Cannabis Market

Anyone looking for a model company in the medical cannabis sector would be well advised to consider Maricann Group Inc (CSE:MARI), as thus far it seems to have done everything right.

With a green ethos that drives both product development and corporate efficiency efforts, Maricann succeeded in becoming one of the first companies in Canada approved to cultivate and sell medical cannabis.

Not content with being an early mover in just its home market, Maricann was quick to stake its claim in another jurisdiction largely overlooked by its peers: Germany.

Read More
Jessica Wong
Maricann CEO Talks C$42.5M Financing Round And German Expansion: 'We Are In A Pole Position'

Javier Hasse, Benzinga, June 14, 2017

Last month, Maricann Group Inc. (CSE:MARI), a vertically integrated medical marijuana producer and distributor, announced it had secured C$42.5 million, or $32.2 million, in non-dilutive financing to increase production in Germany.

This raise was one of the biggest of 2017 and Benzinga reached out to the company’s CEO Ben Ward to chat about the business and the recent developments.

Read More
Linda Burlison
Luke, Geysens High on Maricann Expansion

Norfolk County Mayor Charlie Luke and Coun. Roger Geysens are high on Maricann Group Inc.’s multi million-dollar Langton-area expansion.“It’s phenomenal what they are doing,” said Geysens at the tail end of Tuesday evening’s in-committee meeting. “I think as things go forward, we’ll have the largest one in Canada.”

Read More
Graham Sorkin
Maricann looks to replicate Canada success in newly legal German cannabis market

Anyone looking for a model company in the medical cannabis sector would be well advised to consider Maricann Group Inc (CSE:MARI), as thus far it seems to have done everything right.

With a green ethos that drives both product development and corporate efficiency efforts, Maricann succeeded in becoming one of the first companies in Canada approved to cultivate and sell medical cannabis.

Read More
Graham Sorkin